Background About 13–26% of all acute ischaemic strokes are related to non-valvular atrial
fibrillation, the most common cardiac arrhythmia globally. Deciding when to initiate oral …

… DJ Werring has received speaking honoraria from Bayer in 2016, 2017 and 2018 for talks
and … DJ Seiffge is on scientific advisory boards for Bayer and Pfizer. He also receives for …

Background The effect of early as compared with later initiation of direct oral anticoagulants (DOACs)
in persons with atrial fibrillation who have had an acute ischemic stroke is unclear. …

… Seiffge MD… Seiffge MD … The corresponding author (DJS) had full access to all the
data in the study and takes responsibility for its integrity and the data analysis. …

… One author (DJS) additionally searched EMBASE and Web of science on 12 December
2020. We have excluded Betrixaban from our review due to limited availability outside the US …

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial
treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (…

Background Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors
have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses …

Objective: In patients with recent acute ischemic stroke (AIS) and atrial fibrillation, we
assessed the starting time of direct, non–vitamin K antagonist oral anticoagulants (DOACs) for …

Objective We compared outcomes after treatment with direct oral anticoagulants (DOACs)
and vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and a recent cerebral …

… Two author (DJS and MBG) independently performed the literature research and screened
all titles and abstracts for eligibility. We read the full text of articles potentially eligible for …